These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27758717)

  • 1. Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
    Carratù MR; Signorile A; De Rasmo D; Reale A; Vacca A
    Curr Med Chem; 2016; 23(38):4286-4296. PubMed ID: 27758717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of PP2A.
    O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
    Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
    Westermarck J; Hahn WC
    Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia.
    Toop HD; Dun MD; Ross BK; Flanagan HM; Verrills NM; Morris JC
    Org Biomol Chem; 2016 May; 14(20):4605-16. PubMed ID: 27102578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
    Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products.
    Grossman EA; Ward CC; Spradlin JN; Bateman LA; Huffman TR; Miyamoto DK; Kleinman JI; Nomura DK
    Cell Chem Biol; 2017 Nov; 24(11):1368-1376.e4. PubMed ID: 28919038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of Novel FTY720 Analogs with Anticancer Activity through PP2A Activation.
    Shrestha J; Ki SH; Shin SM; Kim SW; Lee JY; Jun HS; Lee T; Kim S; Baek DJ; Park EY
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30355990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional importance of PP2A regulatory subunit loss in breast cancer.
    Watt LF; Panicker N; Mannan A; Copeland B; Kahl RGS; Dun MD; Young B; Roselli S; Verrills NM
    Breast Cancer Res Treat; 2017 Nov; 166(1):117-131. PubMed ID: 28744751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
    Walter G; Ruediger R
    Cell Cycle; 2012 Feb; 11(3):451-9. PubMed ID: 22262169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, regulation, and pharmacological modulation of PP2A phosphatases.
    Lambrecht C; Haesen D; Sents W; Ivanova E; Janssens V
    Methods Mol Biol; 2013; 1053():283-305. PubMed ID: 23860660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
    Xie F; Bao X; Yu J; Chen W; Wang L; Zhang Z; Xu Q
    Oncotarget; 2015 Sep; 6(28):25660-76. PubMed ID: 26308070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis.
    Ishii Y; Kuroda K; Matsushita K; Yokoo Y; Takasu S; Kijima A; Nohmi T; Ogawa K; Umemura T
    Toxicol Appl Pharmacol; 2017 Dec; 336():75-83. PubMed ID: 29054680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.
    Grech G; Baldacchino S; Saliba C; Grixti MP; Gauci R; Petroni V; Fenech AG; Scerri C
    Tumour Biol; 2016 Sep; 37(9):11691-11700. PubMed ID: 27444275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
    Lu J; Zhuang Z; Song DK; Mehta GU; Ikejiri B; Mushlin H; Park DM; Lonser RR
    J Neurosurg; 2010 Aug; 113(2):225-33. PubMed ID: 20001590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
    Li W; Chen Z; Gong FR; Zong Y; Chen K; Li DM; Yin H; Duan WM; Miao Y; Tao M; Han X; Xu ZK
    Eur J Cancer; 2011 Nov; 47(17):2654-64. PubMed ID: 21958460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
    Cristóbal I; Madoz-Gúrpide J; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Curr Med Res Opin; 2016 Jun; 32(6):1137-41. PubMed ID: 26950691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
    Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein phosphatase 2A as a potential target for anticancer therapy.
    Kalev P; Sablina AA
    Anticancer Agents Med Chem; 2011 Jan; 11(1):38-46. PubMed ID: 21288198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
    Sangodkar J; Perl A; Tohme R; Kiselar J; Kastrinsky DB; Zaware N; Izadmehr S; Mazhar S; Wiredja DD; O'Connor CM; Hoon D; Dhawan NS; Schlatzer D; Yao S; Leonard D; Borczuk AC; Gokulrangan G; Wang L; Svenson E; Farrington CC; Yuan E; Avelar RA; Stachnik A; Smith B; Gidwani V; Giannini HM; McQuaid D; McClinch K; Wang Z; Levine AC; Sears RC; Chen EY; Duan Q; Datt M; Haider S; Ma'ayan A; DiFeo A; Sharma N; Galsky MD; Brautigan DL; Ioannou YA; Xu W; Chance MR; Ohlmeyer M; Narla G
    J Clin Invest; 2017 Jun; 127(6):2081-2090. PubMed ID: 28504649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.